Verily’s Study Watch Rejected By FDA As Parkinson’s Drug-Development Tool

  
Verily’s Study Watch has been rejected by the FDA as a Parkinson’s drug development tool
Verily’s Study Watch has been rejected by the FDA as a Parkinson’s drug development tool • Source: Verily Life Sciences

More from Regulation

More from Policy & Regulation